Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The study aims to evaluate the safety and efficacy of the system in the treatment of atrial fibrillation, marking a new stage in the company's research and development in this field.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues
MEnews•2026/11/04 02:57
AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.
智通财经•2026/11/04 02:51
BNB fell below $690
金色财经•2026/11/04 02:37
Crypto prices
More
Bitcoin
BTC
$76,238.77
-0.72%
Ethereum
ETH
$2,242.97
-0.22%
Tether USDt
USDT
$0.9986
+0.03%
BNB
BNB
$685.9
-1.16%
XRP
XRP
$1.26
+0.49%
USDC
USDC
$0.9998
+0.02%
Solana
SOL
$90.7
-1.40%
TRON
TRX
$0.3213
+0.10%
Hyperliquid
HYPE
$82.32
-0.50%
Zcash
ZEC
$1,174.52
+3.17%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now